TY - JOUR
T1 - Association between testosterone, semen parameters, and live birth in men with unexplained infertility in an intrauterine insemination population
AU - Reproductive Medicine Network
AU - Trussell, J. C.
AU - Coward, R. Matthew
AU - Santoro, Nanette
AU - Stetter, Christy
AU - Kunselman, Allen
AU - Diamond, Michael P.
AU - Hansen, Karl R.
AU - Krawetz, Stephen A.
AU - Legro, Richard S.
AU - Heisenleder, Dan
AU - Smith, James
AU - Steiner, Anne
AU - Wild, Robert
AU - Casson, Peter
AU - Coutifaris, Cristos
AU - Alvero, Reuben R.
AU - Robinson, R. B.
AU - Christman, Greg
AU - Patrizio, Pasquale
AU - Zhang, Heping
AU - Lindgren, Mark C.
N1 - Funding Information:
Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant nos. U10 HD077844, U10 HD077680, U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10HD055925. J.C.T. has nothing to disclose. R.M.C. has nothing to disclose. N.S. has nothing to disclose. C.S. has nothing to disclose. A.K. reports other from Merck. M.P.D. received grants from Yale University and is on the board of directors and stockholder for Advanced Reproductive Care. K.R.H. received grants from Roche Diagnostics and Ferring International Pharmascience Center US. S.A.K. received grants from Merck Sereno and is the editor-in-chief of Systems Biology in Reproductive Medicine. R.S.L. is a consultant for Bayer, Kindex, Odega, Millendo, and AbbVie; site investigator and consultant for Ferring; and received grants from Ferring. D.H. has nothing to disclose. J.S. has nothing to disclose. A.S. reports other from Guerbet. R.W. has nothing to disclose. R.C. has nothing to disclose. C.C. received personal fees from the American Society for Reproductive Medicine. R.R.A. has nothing to disclose. R.B.R. received grants from AbbVie. G.C. received grants and personal fees from AbbVie Pharmaceuticals. P.P. has nothing to disclose. H.Z. has nothing to disclose. M.C.L. has nothing to disclose. Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant nos. U10 HD077844, U10 HD077680, U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10HD055925. We thank Esther Eisenberg, M.D. acting as the NICHD Medical Officer, for her assistance with protocol development and manuscript review. J.C.T. has nothing to disclose. R.M.C. has nothing to disclose. N.S. has nothing to disclose. C.S. has nothing to disclose. A.K. reports other from Merck. M.P.D. received grants from Yale University and is on the board of directors and stockholder for Advanced Reproductive Care. K.R.H. received grants from Roche Diagnostics and Ferring International Pharmascience Center US. S.A.K. received grants from Merck Sereno and is the editor-in-chief of Systems Biology in Reproductive Medicine. R.S.L. is a consultant for Bayer, Kindex, Odega, Millendo, and AbbVie; site investigator and consultant for Ferring; and received grants from Ferring. D.H. has nothing to disclose. J.S. has nothing to disclose. A.S. reports other from Guerbet. R.W. has nothing to disclose. R.C. has nothing to disclose. C.C. received personal fees from the American Society for Reproductive Medicine. R.R.A. has nothing to disclose. R.B.R. received grants from AbbVie. G.C. received grants and personal fees from AbbVie Pharmaceuticals. P.P. has nothing to disclose. H.Z. has nothing to disclose. M.C.L. has nothing to disclose. Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant nos. U10 HD077844, U10 HD077680, U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10HD055925.
Funding Information:
Author Zhang reports grants from NIH during the conduct of the study. Author Robinson reports grants from AbbVie outside the submitted work. Author Christman reports grants from NIH and AbbVie Pharmaceuticals and personal fees from AbbVie Pharmaceuticals during the conduct of the study. Author Alvero reports grants from NICHD, during the conduct of the study. Author Coutifaris reports grants from NIH, personal fees from ASRM (Board Member/President 2017-2018), during the conduct of the study. Author Steiner reports grants from NIH during the conduct of the study and other from Guerbet outside the submitted work. Author Legro reports consultant for Bayer, Kindex, Odega, Millendo, and AbbVie; site investiator and consultant for Ferring; grants from Ferring, outside the submitted work. Author Krawetz reports grants from Merck Sereno and Editor-in-Chief of Systems Biology in Reproductive Medicine for Taylor and Francis, outside the submitted work. Author Hansen reports grants from Roche Diagnostics and Ferring International Pharmascience Center US, during the conduct of the study. Author Diamond reports grants from NIH and Yale University during the conduct of the study and board of directors and stockholder for Advanced Reproductive Care outside the submitted work. Author Kunselman reports grants from NIH during the conduct of the study and other from Merck outside the submitted study. Author Stetter reports grants from NIH during the conduct of the study. All other authors report nothing to disclose.
Funding Information:
This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant nos. U10 HD077844 , U10 HD077680 , U10 HD39005 , U10 HD38992 , U10 HD27049 , U10 HD38998 , U10 HD055942 , HD055944 , U10 HD055936 , and U10HD055925 .
Funding Information:
This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grant nos. U10 HD077844, U10 HD077680, U10 HD39005, U10 HD38992, U10 HD27049, U10 HD38998, U10 HD055942, HD055944, U10 HD055936, and U10HD055925. We thank Esther Eisenberg, M.D. acting as the NICHD Medical Officer, for her assistance with protocol development and manuscript review.
Publisher Copyright:
© 2019
PY - 2019/6
Y1 - 2019/6
N2 - Objective: To determine whether men with unexplained infertility and low total T (TT) have abnormal spermatogenesis and lower fecundity. Design: Secondary analysis of the prospective, randomized, multicenter clinical trial, Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS). Setting: Infertility clinics. Patient(s): Nine hundred couples with unexplained infertility enrolled in AMIGOS. Semen analysis with an ejaculate of at least 5 million total motile sperm was required for enrollment. For inclusion in this secondary analysis, a fasting TT was required. Intervention(s): None. Main Outcome Measure(s): Logistic regression, adjusted for age and body mass index, assessed the association between low TT (defined as <264 ng/dL), semen parameters, and pregnancy outcome. Result(s): Seven hundred eighty-one men (mean age, 34.2 ± 5.7 years) with a median (interquartile range) TT of 411 (318–520) ng/dL were included. Men with TT <264 ng/dL were less likely to have normal (≥4% strict Kruger) morphology (unadjusted odds ratio [OR], 0.56; 95% confidence interval [CI], 0.34, 0.92; adjusted OR, 0.59; 95% CI, 0.35, 0.99). There was no association between low TT and semen volume < 1.5 mL, sperm concentration < 15 × 106/mL, or motility < 40%. Among couples whose male partner had low TT, 21 (18.8%) had a live birth, compared with 184 (27.5%) live births in couples with a male partner having TT > 264 ng/dL. The odds of live birth decreased by 40% in couples whose male partner had low TT (unadjusted OR, 0.60; 95% CI, 0.36, 1.00; adjusted OR, 0.65; 95% CI, 0.38, 1.12). Conclusion(s): In couples with unexplained infertility, low TT in the male partner was associated with abnormal sperm morphology and lower live birth rates. Clinical Trial Registration Number: NCT01044862.
AB - Objective: To determine whether men with unexplained infertility and low total T (TT) have abnormal spermatogenesis and lower fecundity. Design: Secondary analysis of the prospective, randomized, multicenter clinical trial, Assessment of Multiple Intrauterine Gestations from Ovarian Stimulation (AMIGOS). Setting: Infertility clinics. Patient(s): Nine hundred couples with unexplained infertility enrolled in AMIGOS. Semen analysis with an ejaculate of at least 5 million total motile sperm was required for enrollment. For inclusion in this secondary analysis, a fasting TT was required. Intervention(s): None. Main Outcome Measure(s): Logistic regression, adjusted for age and body mass index, assessed the association between low TT (defined as <264 ng/dL), semen parameters, and pregnancy outcome. Result(s): Seven hundred eighty-one men (mean age, 34.2 ± 5.7 years) with a median (interquartile range) TT of 411 (318–520) ng/dL were included. Men with TT <264 ng/dL were less likely to have normal (≥4% strict Kruger) morphology (unadjusted odds ratio [OR], 0.56; 95% confidence interval [CI], 0.34, 0.92; adjusted OR, 0.59; 95% CI, 0.35, 0.99). There was no association between low TT and semen volume < 1.5 mL, sperm concentration < 15 × 106/mL, or motility < 40%. Among couples whose male partner had low TT, 21 (18.8%) had a live birth, compared with 184 (27.5%) live births in couples with a male partner having TT > 264 ng/dL. The odds of live birth decreased by 40% in couples whose male partner had low TT (unadjusted OR, 0.60; 95% CI, 0.36, 1.00; adjusted OR, 0.65; 95% CI, 0.38, 1.12). Conclusion(s): In couples with unexplained infertility, low TT in the male partner was associated with abnormal sperm morphology and lower live birth rates. Clinical Trial Registration Number: NCT01044862.
UR - http://www.scopus.com/inward/record.url?scp=85064243434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064243434&partnerID=8YFLogxK
U2 - 10.1016/j.fertnstert.2019.01.034
DO - 10.1016/j.fertnstert.2019.01.034
M3 - Article
C2 - 30982604
AN - SCOPUS:85064243434
SN - 0015-0282
VL - 111
SP - 1129
EP - 1134
JO - Fertility and sterility
JF - Fertility and sterility
IS - 6
ER -